GlobeNewswire: Avadel Pharmaceuticals plc Contains the last 10 of 216 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:32:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/05/2840377/0/en/Avadel-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals to Present at Upcoming Investor Conferences2024-03-05T13:00:00Z<![CDATA[DUBLIN, Ireland, March 05, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2024/03/04/2839943/0/en/Avadel-Pharmaceuticals-Issues-Statement-On-Patent-Litigation.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals Issues Statement On Patent Litigation2024-03-04T20:37:53Z<![CDATA[DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“Court”) in a patent suit brought by Jazz Pharmaceuticals Inc. regarding LUMRYZ™.]]>https://www.globenewswire.com/news-release/2024/03/04/2839361/0/en/Avadel-Pharmaceuticals-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results2024-03-04T11:30:00Z<![CDATA[-- Generated $19.5 million in fourth quarter and $28.0 million of full year 2023 net revenue from sales of LUMRYZ™ ---- As of January 31st, greater than 2,200 patients enrolled in RYZUPTM and more than 1,200 patients initiated therapy --]]>https://www.globenewswire.com/news-release/2024/02/26/2835083/0/en/Avadel-Pharmaceuticals-to-Provide-a-Corporate-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-4.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 42024-02-26T13:00:00Z<![CDATA[DUBLIN, Ireland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 7:30 a.m. ET on Monday, March 4, 2024, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2023.]]>https://www.globenewswire.com/news-release/2024/02/07/2825138/0/en/Avadel-Pharmaceuticals-to-Present-at-the-Oppenheimer-34th-Annual-Healthcare-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference2024-02-07T13:00:00Z<![CDATA[DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14 at 2:00 p.m. ET.]]>https://www.globenewswire.com/news-release/2024/01/08/2805288/0/en/Avadel-Pharmaceuticals-Announces-Strong-LUMRYZ-Launch-Performance-and-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2023-Financial-Highlights.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights2024-01-08T12:00:00Z<![CDATA[-- Approximately $19 million and $28 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter and full year 2023, respectively ---- Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in RYZUPTM and more than 1,000 patients initiating therapy through December 31 --]]>https://www.globenewswire.com/news-release/2023/11/08/2776063/0/en/Avadel-Pharmaceuticals-Provides-Corporate-Update-and-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results2023-11-08T12:00:00Z<![CDATA[-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch ---- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 --]]>https://www.globenewswire.com/news-release/2023/11/07/2775042/0/en/Avadel-Pharmaceuticals-to-Present-at-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals to Present at Upcoming Investor Conferences 2023-11-07T13:00:00Z<![CDATA[DUBLIN, Ireland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2023/10/30/2769155/0/en/Avadel-Pharmaceuticals-to-Provide-a-Corporate-Update-and-Report-Third-Quarter-Financial-Results-on-November-8.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 82023-10-30T12:00:00Z<![CDATA[DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2023.]]>https://www.globenewswire.com/news-release/2023/10/20/2763975/0/en/Avadel-Pharmaceuticals-Announces-Data-Supporting-Clinical-Profile-for-LUMRYZ-sodium-oxybate-for-extended-release-oral-suspension-CIII-at-World-Sleep-2023.html?f=22&fvtc=4&fvtv=56631Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 20232023-10-20T12:00:00Z<![CDATA[– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option –]]>